Concepts (226)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 6 | 2020 | 1076 | 0.930 |
Why?
|
| Head and Neck Neoplasms | 5 | 2020 | 1052 | 0.840 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2022 | 137 | 0.740 |
Why?
|
| Chemoradiotherapy | 2 | 2020 | 301 | 0.640 |
Why?
|
| Cisplatin | 1 | 2020 | 612 | 0.620 |
Why?
|
| Tertiary Care Centers | 1 | 2014 | 94 | 0.460 |
Why?
|
| Skin Ulcer | 1 | 2012 | 25 | 0.440 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 177 | 0.400 |
Why?
|
| Adenosine Deaminase | 1 | 2011 | 20 | 0.390 |
Why?
|
| Uric Acid | 1 | 2011 | 139 | 0.370 |
Why?
|
| Registries | 1 | 2014 | 702 | 0.360 |
Why?
|
| C-Reactive Protein | 1 | 2011 | 190 | 0.360 |
Why?
|
| Skin | 1 | 2012 | 554 | 0.350 |
Why?
|
| Mouth Neoplasms | 3 | 2020 | 194 | 0.340 |
Why?
|
| Lymph Nodes | 1 | 2012 | 533 | 0.340 |
Why?
|
| Naegleria fowleri | 1 | 2008 | 1 | 0.330 |
Why?
|
| Central Nervous System Protozoal Infections | 1 | 2008 | 1 | 0.330 |
Why?
|
| Amebiasis | 1 | 2008 | 3 | 0.330 |
Why?
|
| Mouth Mucosa | 2 | 2015 | 67 | 0.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2013 | 2438 | 0.250 |
Why?
|
| India | 6 | 2020 | 120 | 0.250 |
Why?
|
| Leiomyosarcoma | 2 | 2015 | 40 | 0.240 |
Why?
|
| Granuloma, Giant Cell | 1 | 2003 | 3 | 0.230 |
Why?
|
| Pharyngeal Diseases | 1 | 2003 | 11 | 0.230 |
Why?
|
| Bone Diseases | 1 | 2003 | 54 | 0.230 |
Why?
|
| Sigmoid Neoplasms | 1 | 2002 | 9 | 0.220 |
Why?
|
| Humans | 36 | 2023 | 86643 | 0.220 |
Why?
|
| Adult | 16 | 2020 | 25648 | 0.220 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2002 | 48 | 0.210 |
Why?
|
| Teratoma | 4 | 2010 | 50 | 0.210 |
Why?
|
| Carcinoma | 2 | 2023 | 436 | 0.210 |
Why?
|
| Penile Neoplasms | 2 | 2015 | 10 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2012 | 2601 | 0.210 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 1939 | 0.210 |
Why?
|
| Aged | 13 | 2020 | 18415 | 0.210 |
Why?
|
| Male | 22 | 2023 | 40965 | 0.200 |
Why?
|
| Female | 22 | 2023 | 44532 | 0.200 |
Why?
|
| Sclerotherapy | 1 | 2001 | 16 | 0.200 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2001 | 33 | 0.200 |
Why?
|
| Abnormalities, Radiation-Induced | 1 | 2001 | 2 | 0.200 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 159 | 0.200 |
Why?
|
| Esophageal Diseases | 1 | 2001 | 26 | 0.200 |
Why?
|
| Middle Aged | 16 | 2023 | 25028 | 0.190 |
Why?
|
| Pancreatectomy | 1 | 2001 | 148 | 0.190 |
Why?
|
| Esophagus | 1 | 2001 | 102 | 0.190 |
Why?
|
| Neoplasms | 2 | 2014 | 2898 | 0.190 |
Why?
|
| Combined Modality Therapy | 5 | 2020 | 1686 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 318 | 0.180 |
Why?
|
| Attitude to Health | 1 | 2001 | 220 | 0.170 |
Why?
|
| Placenta | 1 | 2001 | 175 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 508 | 0.170 |
Why?
|
| Ethanol | 1 | 2001 | 249 | 0.160 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2001 | 229 | 0.160 |
Why?
|
| Prospective Studies | 5 | 2023 | 4213 | 0.160 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2001 | 339 | 0.160 |
Why?
|
| Young Adult | 4 | 2014 | 5976 | 0.150 |
Why?
|
| Survival Rate | 3 | 2020 | 1863 | 0.150 |
Why?
|
| Patient Safety | 1 | 2020 | 212 | 0.150 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 1204 | 0.150 |
Why?
|
| Follow-Up Studies | 5 | 2014 | 3640 | 0.150 |
Why?
|
| Penis | 2 | 2015 | 57 | 0.140 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 567 | 0.140 |
Why?
|
| Hoarseness | 1 | 2015 | 11 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2001 | 645 | 0.140 |
Why?
|
| Vocal Cords | 1 | 2015 | 25 | 0.140 |
Why?
|
| Child | 7 | 2014 | 6927 | 0.130 |
Why?
|
| Doxorubicin | 2 | 2013 | 295 | 0.130 |
Why?
|
| Laryngeal Neoplasms | 1 | 2015 | 89 | 0.130 |
Why?
|
| Prognosis | 4 | 2023 | 3679 | 0.130 |
Why?
|
| Eosinophilic Granuloma | 1 | 2013 | 10 | 0.120 |
Why?
|
| Positron-Emission Tomography | 2 | 2013 | 329 | 0.120 |
Why?
|
| Colitis, Ulcerative | 1 | 2001 | 711 | 0.120 |
Why?
|
| Family Characteristics | 1 | 2014 | 48 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 1075 | 0.120 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2005 | 176 | 0.120 |
Why?
|
| Adolescent | 7 | 2014 | 8981 | 0.120 |
Why?
|
| Demography | 1 | 2014 | 177 | 0.110 |
Why?
|
| Vagus Nerve Diseases | 1 | 2012 | 1 | 0.110 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2012 | 12 | 0.110 |
Why?
|
| Neurilemmoma | 1 | 2012 | 34 | 0.110 |
Why?
|
| Vinblastine | 1 | 2012 | 108 | 0.110 |
Why?
|
| Bleomycin | 1 | 2012 | 98 | 0.110 |
Why?
|
| Mouth Diseases | 1 | 2012 | 15 | 0.110 |
Why?
|
| Dacarbazine | 1 | 2012 | 102 | 0.110 |
Why?
|
| Opportunistic Infections | 1 | 2012 | 59 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2020 | 7993 | 0.100 |
Why?
|
| Melanoma | 1 | 2015 | 459 | 0.100 |
Why?
|
| Plants, Medicinal | 1 | 2011 | 42 | 0.100 |
Why?
|
| Ondansetron | 1 | 2010 | 21 | 0.100 |
Why?
|
| Mycoses | 1 | 2011 | 46 | 0.100 |
Why?
|
| Serotonin Antagonists | 1 | 2010 | 35 | 0.100 |
Why?
|
| Quinuclidines | 1 | 2010 | 26 | 0.100 |
Why?
|
| Isoquinolines | 1 | 2010 | 72 | 0.090 |
Why?
|
| Anti-Infective Agents | 1 | 2011 | 89 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 2360 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 2262 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 275 | 0.090 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2010 | 43 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 894 | 0.090 |
Why?
|
| Bacterial Infections | 1 | 2011 | 182 | 0.090 |
Why?
|
| Antiemetics | 1 | 2010 | 98 | 0.090 |
Why?
|
| Nausea | 1 | 2010 | 175 | 0.090 |
Why?
|
| Plant Extracts | 1 | 2011 | 244 | 0.090 |
Why?
|
| Dexamethasone | 1 | 2010 | 326 | 0.080 |
Why?
|
| Biopsy | 1 | 2012 | 1163 | 0.080 |
Why?
|
| Ceftazidime | 1 | 2008 | 7 | 0.080 |
Why?
|
| Amphotericin B | 1 | 2008 | 34 | 0.080 |
Why?
|
| Cerebrospinal Fluid | 1 | 2008 | 32 | 0.080 |
Why?
|
| Rifampin | 1 | 2008 | 22 | 0.080 |
Why?
|
| Treatment Refusal | 1 | 2008 | 60 | 0.080 |
Why?
|
| Empyema | 1 | 2007 | 9 | 0.080 |
Why?
|
| Chin | 1 | 2007 | 8 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2008 | 293 | 0.080 |
Why?
|
| Cleft Lip | 1 | 2007 | 15 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2014 | 6509 | 0.080 |
Why?
|
| Abscess | 1 | 2007 | 91 | 0.070 |
Why?
|
| Neutrophils | 2 | 2023 | 307 | 0.070 |
Why?
|
| Radiotherapy Dosage | 4 | 2012 | 468 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 1990 | 763 | 0.060 |
Why?
|
| Radiation Injuries | 1 | 2005 | 155 | 0.060 |
Why?
|
| Sex Distribution | 2 | 2001 | 173 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2001 | 2261 | 0.060 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2003 | 30 | 0.060 |
Why?
|
| Skull Base | 1 | 2003 | 47 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 2501 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2003 | 144 | 0.050 |
Why?
|
| Radiation Dosage | 2 | 2000 | 227 | 0.050 |
Why?
|
| Laparotomy | 1 | 2001 | 59 | 0.050 |
Why?
|
| Sclerosing Solutions | 1 | 2001 | 5 | 0.050 |
Why?
|
| Tissue Extracts | 1 | 2001 | 24 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2001 | 235 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2001 | 83 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 938 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 464 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2003 | 353 | 0.050 |
Why?
|
| Esophagoscopy | 1 | 2001 | 87 | 0.050 |
Why?
|
| Age Distribution | 1 | 2001 | 204 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2007 | 2903 | 0.050 |
Why?
|
| Tobacco Use | 1 | 2020 | 24 | 0.050 |
Why?
|
| Health Surveys | 1 | 2001 | 239 | 0.050 |
Why?
|
| Incidence | 2 | 2001 | 1577 | 0.040 |
Why?
|
| Patient Participation | 1 | 2001 | 216 | 0.040 |
Why?
|
| Dengue | 1 | 1998 | 43 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 1998 | 154 | 0.040 |
Why?
|
| Tongue Neoplasms | 1 | 1997 | 50 | 0.040 |
Why?
|
| Lung | 1 | 2023 | 1170 | 0.040 |
Why?
|
| Glottis | 1 | 2015 | 11 | 0.030 |
Why?
|
| Sphenoid Bone | 1 | 1995 | 9 | 0.030 |
Why?
|
| Ependymoma | 1 | 1995 | 17 | 0.030 |
Why?
|
| Larynx | 1 | 2015 | 38 | 0.030 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1995 | 48 | 0.030 |
Why?
|
| Meningeal Neoplasms | 1 | 1995 | 61 | 0.030 |
Why?
|
| Meningioma | 1 | 1995 | 60 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1995 | 100 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2023 | 8489 | 0.030 |
Why?
|
| Radiography, Panoramic | 1 | 2013 | 7 | 0.030 |
Why?
|
| Gingiva | 1 | 2013 | 8 | 0.030 |
Why?
|
| Prednisolone | 1 | 2013 | 41 | 0.030 |
Why?
|
| Vincristine | 1 | 2013 | 111 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2013 | 299 | 0.030 |
Why?
|
| Proteus Infections | 1 | 2012 | 1 | 0.030 |
Why?
|
| Candidiasis, Oral | 1 | 2012 | 4 | 0.030 |
Why?
|
| Staphylococcus epidermidis | 1 | 2012 | 14 | 0.030 |
Why?
|
| Fungemia | 1 | 2012 | 15 | 0.030 |
Why?
|
| Klebsiella Infections | 1 | 2012 | 25 | 0.030 |
Why?
|
| Escherichia coli Infections | 1 | 2012 | 35 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2012 | 220 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2012 | 41 | 0.030 |
Why?
|
| Pseudomonas Infections | 1 | 2012 | 95 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 1721 | 0.030 |
Why?
|
| Bacteremia | 1 | 2012 | 99 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2011 | 143 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 546 | 0.020 |
Why?
|
| Fungi | 1 | 2011 | 65 | 0.020 |
Why?
|
| Radiation Protection | 1 | 1990 | 25 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 1139 | 0.020 |
Why?
|
| alpha-Fetoproteins | 1 | 2010 | 45 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 255 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2010 | 399 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2010 | 71 | 0.020 |
Why?
|
| Nigeria | 1 | 2010 | 152 | 0.020 |
Why?
|
| Infant | 2 | 2010 | 3046 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1565 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2010 | 3612 | 0.020 |
Why?
|
| Vomiting | 1 | 2010 | 193 | 0.020 |
Why?
|
| Animals | 1 | 2008 | 26582 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 826 | 0.020 |
Why?
|
| Biomarkers, Tumor | 2 | 2010 | 1464 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2007 | 2379 | 0.020 |
Why?
|
| Rectum | 1 | 2009 | 146 | 0.020 |
Why?
|
| Bacteria | 1 | 2011 | 447 | 0.020 |
Why?
|
| Palliative Care | 1 | 2009 | 257 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 2767 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2007 | 150 | 0.020 |
Why?
|
| Colon | 1 | 2009 | 496 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2005 | 119 | 0.020 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1985 | 47 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2007 | 695 | 0.020 |
Why?
|
| Testicular Neoplasms | 1 | 1985 | 105 | 0.020 |
Why?
|
| Mammography | 1 | 2007 | 463 | 0.020 |
Why?
|
| Platelet Factor 4 | 1 | 2003 | 11 | 0.010 |
Why?
|
| Comorbidity | 1 | 2007 | 943 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1995 | 3362 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2003 | 56 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2003 | 55 | 0.010 |
Why?
|
| Lymphokines | 1 | 2003 | 76 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2003 | 57 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 179 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2003 | 270 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 376 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 5417 | 0.010 |
Why?
|
| Time Factors | 1 | 2010 | 5210 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 407 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2005 | 1078 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2003 | 311 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2003 | 839 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2000 | 188 | 0.010 |
Why?
|
| Age of Onset | 1 | 2001 | 310 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2000 | 292 | 0.010 |
Why?
|
| Climate | 1 | 1998 | 50 | 0.010 |
Why?
|
| Mastectomy | 1 | 2000 | 243 | 0.010 |
Why?
|
| Parotid Gland | 1 | 1997 | 31 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 274 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1998 | 293 | 0.010 |
Why?
|
| Spinal Cord | 1 | 1995 | 249 | 0.010 |
Why?
|
| Dysgerminoma | 1 | 1985 | 7 | 0.000 |
Why?
|